IGR Blood Cancer Drugs Market Haga clic para leer
  • Comentarios

IGR

Blood Cancer Drugs Market

Publicado el en “Salud y Estado Físico, Negocios”, Idioma — English. 5 páginas.
The report on Blood Cancer Drugs Market by product (rituaxan/mabthera, gleevac/glivec, revlimid, velcade, tasigna, pomalyst, vidaza, kyprolis, adcetris, and others) trends analysis and forecasts up to 2023 studies the market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Blood Cancer Drugs Market is projected to grow at a CAGR between 10.5% to 11.5% in terms of value over the period of Más
Mostrar Etiquetas

Otras publicaciones de “IGR”

Ver todas las publicaciones